

TOXICOLOGICAL PROFILE FOR URANIUM

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry

February 2013

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

UPDATE STATEMENT

A Toxicological Profile for Uranium, Draft for Public Comment was released in May 2011. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
1600 Clifton Road NE
Mailstop F-57
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the toxic substances each profile describes. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. A health effects summary describes the adequacy of information to determine a substance's health effects. ATSDR identifies data needs that are significant to protection of public health.

Each profile:

- (A) Examines, summarizes, and interprets available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) Determines whether adequate information on the health effects of each substance is available or being developed to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are federal, state, and local health professionals; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists also have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher J. Portier, Ph.D.
Assistant Administrator

Agency for Toxic Substances and Disease Registry

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four sections in each Toxicological Profile address child health issues:

- Section 1.6** **How Can (Chemical X) Affect Children?**
- Section 1.7** **How Can Families Reduce the Risk of Exposure to (Chemical X)?**
- Section 3.7** **Children's Susceptibility**
- Section 6.6** **Exposures of Children**

Other Sections of Interest:

- Section 3.8** **Biomarkers of Exposure and Effect**
 - Section 3.11** **Methods for Reducing Toxic Effects**
-

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) **Fax:** (770) 488-4178
E-mail: cdcinfo@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. Department of Energy, the World Health Organization, and the International Atomic Energy Agency in the medical management of radiation accidents. A 24-hour emergency response program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, consults, or assists in the response to all kinds of radiation accidents. Contact: Oak Ridge Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 • Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for REAC/TS) • e-mail: cooleyp@ornl.gov • website (including emergency medical guidance): <http://www.ornl.gov/reacts/default.htm>.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

This page is intentionally blank.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Sam Keith, M.S., CHP
Obaid Faroon, D.V.M, Ph.D.
Nickolette Roney, M.P.H.
Franco Scinicariello, M.D., M.P.H.
Sharon Wilbur, M.A.
ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA

Lisa Ingerman, Ph.D., DABT
Fernando Lladós, Ph.D.
Daneil Plewak, B.S.
David Wohlers, Ph.D.
Gary Diamond, Ph.D.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for uranium. The panel consisted of the following members:

1. Rudolfs K. Zalups, Ph.D., Mercer University School of Medicine, Macon, Georgia;
2. Walter W. Piegorsch, Ph.D., University of Arizona, Tucson, Arizona;
3. Fletcher F. Hahn, DVM, Ph.D., DACVP, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.

These experts collectively have knowledge of uranium and uranium compound's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	xi
PEER REVIEW	xiii
CONTENTS	xv
LIST OF FIGURES	xix
LIST OF TABLES	xxi
1. PUBLIC HEALTH STATEMENT FOR URANIUM	1
2. RELEVANCE TO PUBLIC HEALTH	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO URANIUM IN THE UNITED STATES	11
2.2 SUMMARY OF HEALTH EFFECTS	13
2.3 MINIMAL RISK LEVELS (MRLs)	20
3. HEALTH EFFECTS	39
3.1 INTRODUCTION	39
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	41
3.2.1 Inhalation Exposure	42
3.2.1.1 Death	43
3.2.1.2 Systemic Effects	46
3.2.1.3 Immunological and Lymphoreticular Effects	98
3.2.1.4 Neurological Effects	100
3.2.1.5 Reproductive Effects	101
3.2.1.6 Developmental Effects	102
3.2.1.7 Cancer	103
3.2.2 Oral Exposure	108
3.2.2.1 Death	109
3.2.2.2 Systemic Effects	110
3.2.2.3 Immunological and Lymphoreticular Effects	151
3.2.2.4 Neurological Effects	152
3.2.2.5 Reproductive Effects	155
3.2.2.6 Developmental Effects	158
3.2.2.7 Cancer	161
3.2.3 Dermal Exposure	162
3.2.3.1 Death	162
3.2.3.2 Systemic Effects	163
3.2.3.3 Immunological and Lymphoreticular Effects	174
3.2.3.4 Neurological Effects	174
3.2.3.5 Reproductive Effects	174
3.2.3.6 Developmental Effects	174
3.2.3.7 Cancer	175
3.2.4 Other Routes of Exposure	175
3.3 GENOTOXICITY	184
3.4 TOXICOKINETICS	193
3.4.1 Absorption	193

3.4.1.1	Inhalation Exposure	193
3.4.1.2	Oral Exposure	195
3.4.1.3	Dermal Exposure	197
3.4.2	Distribution	198
3.4.2.1	Inhalation Exposure	198
3.4.2.2	Oral Exposure	201
3.4.2.3	Dermal Exposure	204
3.4.2.4	Other Routes of Exposure	205
3.4.3	Metabolism	205
3.4.4	Elimination and Excretion	206
3.4.4.1	Inhalation Exposure	206
3.4.4.2	Oral Exposure	209
3.4.4.3	Dermal Exposure	210
3.4.4.4	Other Routes of Exposure	210
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	210
3.5	MECHANISMS OF ACTION	233
3.5.1	Pharmacokinetic Mechanisms	233
3.5.2	Mechanisms of Toxicity	234
3.5.3	Animal-to-Human Extrapolations	236
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	237
3.7	CHILDREN'S SUSCEPTIBILITY	238
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	242
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Uranium	243
3.8.2	Biomarkers Used to Characterize Effects Caused by Uranium	244
3.9	INTERACTIONS WITH OTHER CHEMICALS	245
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	245
3.11	METHODS FOR REDUCING TOXIC EFFECTS	246
3.11.1	Reducing Peak Absorption Following Exposure	246
3.11.2	Reducing Body Burden	247
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	248
3.12	ADEQUACY OF THE DATABASE	248
3.12.1	Existing Information on Health Effects of Uranium	249
3.12.2	Identification of Data Needs	251
3.12.3	Ongoing Studies	262
4.	CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION	263
4.1	CHEMICAL IDENTITY	263
4.2	PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES	263
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	273
5.1	PRODUCTION	273
5.2	IMPORT/EXPORT	280
5.3	USE	280
5.4	DISPOSAL	284
6.	POTENTIAL FOR HUMAN EXPOSURE	287
6.1	OVERVIEW	287
6.2	RELEASES TO THE ENVIRONMENT	291
6.2.1	Air	292
6.2.2	Water	296
6.2.3	Soil	298

6.3	ENVIRONMENTAL FATE	300
6.3.1	Transport and Partitioning.....	300
6.3.2	Transformation and Degradation	305
6.3.2.1	Air	305
6.3.2.2	Water.....	306
6.3.2.3	Sediment and Soil	306
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	307
6.4.1	Air	308
6.4.2	Water.....	308
6.4.3	Sediment and Soil	318
6.4.4	Other Environmental Media.....	320
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	321
6.6	EXPOSURES OF CHILDREN.....	329
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	331
6.8	ADEQUACY OF THE DATABASE	334
6.8.1	Identification of Data Needs	334
6.8.2	Ongoing Studies.....	338
7.	ANALYTICAL METHODS.....	339
7.1	BIOLOGICAL MATERIALS.....	339
7.1.1	Internal Uranium Measurements.....	342
7.1.2	External Measurements.....	343
7.2	ENVIRONMENTAL SAMPLES	345
7.2.1	Field Measurements of Uranium.....	345
7.2.2	Collection of Environmental Samples.....	346
7.2.3	Laboratory Analysis of Environmental Samples.....	347
7.3	ADEQUACY OF THE DATABASE	354
7.3.1	Identification of Data Needs	354
7.3.2	Ongoing Studies.....	357
8.	REGULATIONS, ADVISORIES, AND GUIDELINES.....	359
9.	REFERENCES	371
10.	GLOSSARY	427
APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE.....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1
D.	OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, AND BIOLOGY	D-1
E.	INDEX.....	E-1

This page is intentionally blank.

LIST OF FIGURES

3-1. Levels of Significant Exposure to Uranium – Inhalation	74
3-2. Levels of Significant Exposure to Uranium – Oral	131
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance.....	212
3-4. Respiratory Tract Compartments in Which Particles May be Deposited.....	215
3-5. Environmental Pathways for Potential Human Health Effects from Uranium.....	218
3-6. The Human Respiratory Tract Model: Absorption into Blood.....	222
3-7. Structure of the Human Alimentary Tract Model (HATM)	224
3-8. Biokinetic Model for Uranium after Uptake to Blood.....	225
3-9. Multicompartmental Model for Uranium after Uptake to Blood.....	228
3-10. Multicompartmental Model.....	230
3-11. Existing Information on Health Effects of Uranium	250
5-1. Uranium Ore Processing.....	276
6-1. Frequency of NPL Sites with Uranium Contamination.....	288
6-2. Environmental Pathways for Potential Human Health Effects from Uranium.....	301
6-3. Average Uranium Concentrations in Drinking Water for States Where Concentration Exceeds 1 pCi/L	313

This page is intentionally blank.

LIST OF TABLES

2-1. Renal Effects Following Intermediate-Duration Inhalation Exposure to Insoluble Uranium Compounds	23
2-2. Renal Effects Following Intermediate-Duration Inhalation Exposure to Soluble and Poorly Soluble Uranium Compounds.....	25
3-1. Levels of Significant Exposure to Uranium – Inhalation	47
3-2. Levels of Significant Exposure to Uranium – Oral	111
3-3. Levels of Significant Exposure to Uranium – Dermal	164
3-4. Summary of Significant Observations in Studies of a Cohort of Gulf War Veterans Exposed to Depleted Uranium.....	177
3-5. Genotoxicity of Uranium <i>In Vivo</i>	187
3-6. Genotoxicity of Uranium <i>In Vitro</i>	190
3-7. Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity.....	216
3-8. Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract.....	219
3-9. Sensitivity and Calculated Transfer Coefficients (d^{-1}).....	231
4-1. Chemical Identity of Uranium Metal.....	264
4-2. Physical and Chemical Properties of Selected Uranium Compounds	265
4-3. Percent Occurrence and Radioactive Properties of Naturally Occurring Isotopes of Uranium.....	268
4-4. ^{235}U and ^{238}U Decay Series Showing Sources and Decay Products	269
5-1. Uranium Ores	274
5-2. Uranium Production in the United States by Uranium Mills and Other Sources	278
5-3. Uranium Mining Production, 1985–2009.....	279
5-4. Import of Uranium and Compounds (in kg) into the United States (1990–1998).....	281
5-5. Export of Uranium and Compounds (in kg) (1990–1998)	282
5-6. Foreign Purchases and Foreign Sales of Uranium (kg U_3O_8 Equivalent) by U.S. Suppliers and Owners and Operators of U.S. Civilian Nuclear Power Reactors, 1994–2009.....	283

6-1. Normalized Uranium Effluent Discharges from Uranium Mining, Milling, Conversion, Enrichment, and Fuel Fabrication.....	293
6-2. Uranium in Airborne Particles (Composites)	309
6-3. Uranium in Drinking Water (Composites)	314
6-4. Uranium Analyses of Select Precipitation Composite Samples March–May 1996	315
6-5. Uranium in Rocks and Soils	319
6-6. Concentrations of Uranium in Some Foods.....	322
6-7. Geometric Mean and Selected Percentile of Urinary Concentrations of Uranium ($\mu\text{g/g}$ Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES)	324
6-8. Geometric Mean and Selected Percentile of Urinary Concentrations of Uranium ($\mu\text{g/L}$) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES)	326
6-9. Urinary Levels of Uranium in Individuals Exposed through Military Use of Depleted Uranium.....	333
7-1. Analytical Methods for Determining Uranium in Biological Samples	340
7-2. Analytical Methods for Determining Uranium in Environmental Samples	348
7-3. Additional Analytical Methods for Determining Uranium in Environmental Samples	355
8-1. Regulations, Advisories, and Guidelines Applicable to Uranium.....	361